RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer , its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling In Vitro RTC-5 (0-40 μM; 48 hours) inhibits H1650 lung adenocarcinoma cell growth with an GI 50 of 12.6μM. RTC-5 (20-40 μM; 24 hours) negatively regulates PI3K-AKT and RAS-ERK pathways by decreasing phospho-AKT and phospho-ERK levels expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: H1650 lung adenocarcinoma cells Concentration: 0 μM, 1 μM, 10 μM, 20 μM, 30 μM, 40 μM Incubation Time: 48 hours Result: Inhibited H1650 lung adenocarcinoma cell growth. Western Blot AnalysisCell Line: H1650 lung adenocarcinoma cells Concentration: 20 μM, 40 μM Incubation Time: 24 hours Result: Decreased p-AKT, p-ERK expression. Form:Solid IC50& Target:IC50: EGFR